Contact
      Please use this form to send email to PR contact of this press release:
      
      Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program
    
      TO:
      
      David Craig
      
      Sarcomatrix, Inc.
      
      +1 415-246-3311